Every one of those 1 sits in a single category, pharma. Center for Biological Diversity is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 9 original sources on average. We currently track 1 Biotech story that mention alligator snapping turtle, all published on July 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about alligator snapping turtle
Every one of those 1 sits in a single category, pharma. Center for Biological Diversity is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 9 original sources on average. We currently track 1 Biotech story that mention alligator snapping turtle, all published on July 18, 2026.
Stories tracked
1
Sources per story
9
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering alligator snapping turtle. Shared-story counts are live from our verified record — not editorial picks.
The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.